{"ticker": {"uuid": "7555715d-c2ed-474e-bc0b-743685f6d31f", "symbol": "VIVS", "name": "VivoSim Labs, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "VivoSim Enters China with First Commercial Sales of NAMkind\u2122 Toxicology Screening and Efficacy Testing Services", "summary": "VivoSim Labs, Inc. announced its first commercial sales in China for its NAMkind\u2122 toxicology screening and efficacy testing services, marking a significant expansion into the world's second-largest pharmaceutical market. The initial engagements involve a Shanghai-based oncology b", "url": "https://www.globenewswire.com/news-release/2026/07/21/3330426/0/en/VivoSim-Enters-China-with-First-Commercial-Sales-of-NAMkind-Toxicology-Screening-and-Efficacy-Testing-Services.html", "source_name": "GlobeNewswire", "published_at": "2026-07-22T03:10:29", "published_display": "22 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOMXp5YlRxRFJzMU53VnVTRmNMdi11MV9iZXNIaVZBdE4wNS1aUEZMdUZSTUxIb0lXNGN4bWhCQnV6Zks5SDFVMnNveEZwYzlnQ21tMXNwQm0yV2N5V245N01TZjlZbXk5V1BlM3pPYVYzUnQydW5oalg1T0Nrd056a2p1M1RIbFoyUHhOaUh5TmxzYXVVZVpXUEJKX1VNdERl?oc=5", "source_name": "Market source", "published_at": "2026-07-21T14:28:16+00:00", "published_display": "21 Jul 2026 14:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Enters China Market With Initial Preclinical Testing Contracts", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivosim-enters-china-market-initial-133504256.html", "source_name": "MT Newswires", "published_at": "2026-07-21T13:35:04+00:00", "published_display": "21 Jul 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Prices $4.0 Million Private Placement and Amends Legacy Armistice Warrants", "summary": "VivoSim Labs (VIVS) announced a $4.0 million private placement consisting of pre-funded and common warrants, with proceeds intended for working capital and general corporate purposes. The company engaged A.G.P./Alliance Global Partners as the placement agent. Additionally, VivoSi", "url": "https://www.tradingview.com/news/tradingview:441097d729cce:0-vivosim-labs-prices-4-0-million-private-placement-and-amends-legacy-armistice-warrants/", "source_name": "TradingView", "published_at": "2026-07-17T12:40:53", "published_display": "17 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxOSHllM2hCLXVQU3B3RWQ2cGFVU1dSV3k4WXNNc09NZGhTY0lITlAzdjlXUThlVGVscWpMZGZmOTZZVjJmanpiOXFSLXU5Nmp3Qm1HWGtROWkxVVJLUmxLYkpoRUZQWFRsVWE2SEpIX0hORFJBYlkyWlhWdjItTGpNN3d1eDQ0TlJPMThESnZneURMWHhmc1BCOUI3TzFsel9QS2VQTjFVdXl0R3lxcUVGR2dzbUlrUDRFU2xTZ2JRSHJvS1NxQnhPYzNVZkpLQS0zMmFhMTUyMG9MUnJHaEdzNzNjejE0Tm9Dc1RTcDdIMFVMQTctYUVPVmxvSmNWZndmMldNVmJrRG1NcGppRmIwVWxjTGFHZWdFT2F6REZ1NzNhcDg0UFdUVXQxT3dqdw?oc=5", "source_name": "Sahm", "published_at": "2026-07-17T07:51:56+00:00", "published_display": "17 Jul 2026 07:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is VivoSim Labs stock falling Thursday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWjlrTUNXTlpZYlNyQ1J2RXg2LV91SmtydmVnZ3lWUlIxbXNyLXZ5SXJFWjR5cGVNRExodWNSMHY3VFhESWpZdWIyb2pWNFdhM2o3OE1WeEo3ZkdCLWoxTUN3SlM3cnJGZ3ExMHBtMUk4aG5DaEZuY0swcDZxc0xLVVA0Z2RWQXFITm9mSzVZNVl2Wi1vakVweFEzcWYzdjBEN29uZEdDY3p3T3ZTQ0Ixc09R?oc=5", "source_name": "MSN", "published_at": "2026-07-17T07:00:00+00:00", "published_display": "17 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs prices USD 4 million private placement at USD 0.85 per share", "summary": "VivoSim Labs has priced a $4 million private placement at $0.85 per share and warrant with a single healthcare-focused institutional investor. The deal includes 4,705,883 common shares and warrants, with the warrants becoming exercisable after shareholder approval and expiring in", "url": "https://www.bitget.com/amp/news/detail/12560605510574", "source_name": "Bitget", "published_at": "2026-07-17T02:40:53", "published_display": "17 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment", "summary": "VivoSim Labs has secured $4.0 million through a private placement with a healthcare-focused institutional investor, involving the sale of common stock and warrants at $0.85 per share. Existing warrants will also be amended to lower their exercise price to $0.85, subject to shareh", "url": "https://www.quiverquant.com/news/VivoSim+Labs+Announces+$4.0+Million+Private+Placement+with+Institutional+Investor+and+Warrant+Amendment", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T01:40:17", "published_display": "17 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs raises $4M in private placement", "summary": "VivoSim Labs (NASDAQ:VIVS) has raised approximately $4.0 million through a private placement with a healthcare-focused institutional investor, selling shares and warrants at $0.85 per share. The company will use these proceeds for working capital and general corporate purposes. T", "url": "https://m.uk.investing.com/news/stock-market-news/vivosim-labs-raises-4m-in-private-placement-93CH-4774090?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-17T00:40:12", "published_display": "17 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs raises $4M in private placement By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNRTZWeDUzbnRYUDhrRW1FQmw0MTFJWlluTzN2c2QwVVRZMEdEVHlZQmFFS09fNjhBaUVxVk9Rc0tqVVZuSUtmRXlpdlFlMmRDYmdvb1NUdDE4RHFCdG9ibFFIT0IzSzRoTElVVHNfdjFTeGUyaDhnS1QyVWlUcXMtaXZObXpra0l0S1U2VTk3Z2RFYW9OQlhtMHBjRUxfZGpNOWIwMGRpcw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T22:32:09+00:00", "published_display": "16 Jul 2026 22:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VivoSim Labs Prices $4 Million Private Placement of Stock, Warrants; Shares Fall Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vivosim-labs-prices-4-million-131934088.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:19:34+00:00", "published_display": "16 Jul 2026 13:19", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs, Inc. announced that it expects to receive $4.000001 million in funding", "summary": "VivoSim Labs, Inc. has announced a securities purchase agreement with a healthcare-focused institutional investor for $4,000,000.55 in gross proceeds. This funding involves the sale of 4,705,883 common shares and pre-funded warrants, with an issue price and exercise price of $0.8", "url": "https://www.marketscreener.com/news/vivosim-labs-inc-announced-that-it-expects-to-receive-4-000001-million-in-funding-ce7f5ed3d18af225", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T13:09:39", "published_display": "16 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vivosim Labs Shares Are Rocketing on Wednesday?", "summary": "VivoSim Labs Inc. (NASDAQ: VIVS) shares surged on Wednesday due to a $5 million milestone payment received from Eli Lilly and Company (NYSE: LLY) and optimistic revenue guidance for FY2027, anticipating over 500% growth. The payment was triggered by the first patient being dosed ", "url": "https://www.sahmcapital.com/news/content/why-vivosim-labs-shares-are-rocketing-on-wednesday-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T10:12:21", "published_display": "16 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Sees FY27 Rev Growing Significantly >VIVS", "summary": "VivoSim Labs (VIVS) projects significant revenue growth for fiscal year 2027. The company's outlook indicates a strong financial performance in the coming years. This forecast suggests positive momentum for VIVS.", "url": "https://www.moomoo.com/news/post/73010316/vivosim-labs-sees-fy27-rev-growing-significantly-vivs", "source_name": "Moomoo", "published_at": "2026-07-16T02:10:05", "published_display": "16 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is VivoSim Labs stock sliding today?", "summary": "VivoSim Labs (VIVS) stock slid 1.5% in after-hours trading, reversing an intraday surge. The initial rally was triggered by a $5 million milestone payment from Eli Lilly and a projection of over 500% revenue growth for fiscal year 2027 due to demand for its NAMkind 3D cellular mo", "url": "https://www.investing.com/news/stock-market-news/why-is-vivosim-labs-stock-sliding-today-93CH-4794427", "source_name": "Investing.com", "published_at": "2026-07-16T00:15:35", "published_display": "16 Jul 2026 00:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs (NASDAQ:VIVS) hits $5M milestone; company says 500% revenue jump comes off $131K base", "summary": "VivoSim Labs (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly and Company (NYSE:LLY) after the first patient was dosed in a Phase 2 trial for an inflammatory bowel drug. Despite this significant payment, which is 1.7 times VivoSim\u2019s equity value, shares closed", "url": "https://ts2.tech/en/vivosim-labs-nasdaqvivs-hits-5m-milestone-company-says-500-revenue-jump-comes-off-131k-base/", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T21:15:35", "published_display": "15 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim receives $5M milestone payment from Eli Lilly By Investing.com", "summary": "VivoSim Labs Inc. (NASDAQ:VIVS) announced today it has received a $5 million milestone payment from Eli Lilly related to a former inflammatory bowel disease drug program. This payment marks the dosing of the first patient in Phase 2 studies of the drug, with potential for up to $", "url": "https://ng.investing.com/news/stock-market-news/vivosim-receives-5m-milestone-payment-from-eli-lilly-93CH-2600771", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T20:12:06", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs (VIVS) Forecasts 500% Revenue Growth, Secures $5M M", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNa2JWelFUVHFGX0ZOTmJza3VNbTFXRmcyVHlqR1RuaEV4TWZvWGFoc3dwRWs1MjRTUTk5cjlLaVAyemhlekctNjdueFNmWFIxcFpUMG5GU0FoazFqdjNpUS1aYUs0ZWhtby1naVh0X1NlVkMwcWR2RzJnaFNvVnJsS2QzekNrVmFuOGw4V0YtYWRjM0J5YUE1XzlqSGlROHJYVDVGQ3pfd1k1MndKSnhyU0QzeXY1YVVWQm91RVM1Ym5qcHpX?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T19:00:47+00:00", "published_display": "15 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Rallies on Heavy Volume After Late Annual Report Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPYmNoTXZmZDd5WjIyVW1EQTBPQ0Fka3VSbkdPcXJLSENhQ1p5MFJxb2tmY3Vrd18wcUkyeXpkVGpTY2VaUUJGN2ZfS0RBNzFMZmxzbHlIb2pvb2VKSDNoQnMwUW4xWmdEZXd1N1o1NU1obGZQdW5nSXhNbjRhQUZ5Z2xrS2d1M0kwZkZMS1lDZHNxazVzcTBjcVFyY2I4TzhpYkpR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T16:21:00+00:00", "published_display": "15 Jul 2026 16:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim receives $5 million Eli Lilly milestone", "summary": "VivoSim received a $5 million milestone payment from Eli Lilly after the first patient was dosed in Phase 2 studies for an acquired inflammatory bowel disease (IBD) drug. VivoSim, which sold its FXR314 IBD program to Eli Lilly in March 2025, could earn an additional $45 million i", "url": "https://grafa.com/en/news/united-states/vivosim-5-million-eli-lilly-milestone-fy2027-guidance", "source_name": "grafa.com", "published_at": "2026-07-15T17:15:35", "published_display": "15 Jul 2026 17:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth", "summary": "", "url": "https://finance.yahoo.com/m/8711fa04-b005-37fb-ab5a-a936fdf8de8b/vivosim-receives-%245-million.html", "source_name": "InvestorsHub", "published_at": "2026-07-15T14:46:50+00:00", "published_display": "15 Jul 2026 14:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs stock falls 29% on $4M private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdWdoLWlxOUVacXlpc0VFa1gyTlpGNGhUbkNZZjhGdkVSMlVWR3BXX1RkR1lsY3k1ckw4YzkybDI1eGZneWlBaTJ6aHRsaXFIMXZnVDFwQzdaUklkY1E5UDExWF96Q0hWUkZlZHZHWWNrbmk5cUF2WjN3aDN5d3NtY1ZDaFRGeUJhUFlESzQ4NnNkUldTVFp3eXphbTZ5c1FuREtBTFkydw?oc=5", "source_name": "scanx.trade", "published_at": "2026-07-15T14:10:33+00:00", "published_display": "15 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Receives $5 Million Eli Lilly Milestone Payment, Issues Fiscal 2027 Revenue Growth Outlook", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivosim-receives-5-million-eli-131234676.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:12:34+00:00", "published_display": "15 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS Stock Whipsaws As Traders Target Volatile Moves", "summary": "VivoSim Labs Inc. (VIVS) stock is experiencing extreme volatility, with prices swinging dramatically from premarket spikes to sharp intraday drops. The company, an early-stage story with minimal revenue ($40,000 quarterly) and significant losses (net loss of $5.76M), is attractin", "url": "https://stockstotrade.com/news/vivosim-labs-inc-vivs-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T14:08:00", "published_display": "15 Jul 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027", "summary": "VivoSim Labs, Inc. announced receipt of a $5 million milestone payment from Eli Lilly related to an inflammatory bowel disease drug program previously sold to Lilly, triggered by the dosing of the first patient in Phase 2 studies. VivoSim remains eligible for up to an additional ", "url": "https://sg.finance.yahoo.com/news/vivosim-receives-5m-milestone-payment-120500732.html", "source_name": "Market source", "published_at": "2026-07-15T12:15:35", "published_display": "15 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS Stock Whipsaws As Traders Zero In On Cash Runway", "summary": "VivoSim Labs Inc. (VIVS) stock experienced significant volatility, driven by news of an AI partnership. Despite low revenue ($40,000) and substantial net losses ($5.76M), the company maintains a cash buffer of $5.0M and low debt, attracting speculative traders due to its early-st", "url": "https://www.timothysykes.com/news/vivosim-labs-inc-vivs-news-2026_07_15/", "source_name": "www.timothysykes.com", "published_at": "2026-07-15T09:18:00", "published_display": "15 Jul 2026 09:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Phase 2 Patient Brings VivoSim a $5M Lilly Payment", "summary": "VivoSim (VIVS) announced it received a $5 million milestone payment from Eli Lilly, contingent on the first patient dosing in Phase 2 studies for an inflammatory bowel disease drug VivoSim previously sold. The company is eligible for an additional $45 million in milestones and pr", "url": "https://www.stocktitan.net/news/VIVS/vivo-sim-receives-5m-milestone-payment-from-eli-lilly-provides-omwzf1tsza0a.html", "source_name": "Stock Titan", "published_at": "2026-07-15T08:05:00", "published_display": "15 Jul 2026 08:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim: Fiscal Q4 Earnings Snapshot", "summary": "VivoSim Labs, Inc. (VIVS) reported a fiscal fourth-quarter net loss of $5.8 million, or $2.21 per share, with revenues of $40,000. For the full year, the company's loss totaled $13.8 million, or $5.35 per share, on revenues of $131,000. VivoSim Labs is a development-stage company", "url": "https://www.ktvb.com/article/syndication/associatedpress/vivosim-fiscal-q4-earnings-snapshot/616-6e456e35-fc14-4480-bb1a-28886fd71185", "source_name": "KTVB", "published_at": "2026-07-14T21:10:27", "published_display": "14 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting", "summary": "VivoSim Labs, Inc. announced that data from its advanced 3D human tissue models will be featured at the European Society of Toxicology\u2019s annual conference. The data demonstrate the superior predictive power of VivoSim's AI-enabled NAMkind\u2122 Liver and NAMkind\u2122 GI platforms for live", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318919/37000/en/vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-prediction-at-european-toxicology-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T07:09:23", "published_display": "30 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs(VIVS) Stock Options Chain | Quotes & News", "summary": "This article provides financial information for VivoSim Labs (VIVS), including its stock options chain, quotes, and related news. It serves as a portal for investors to access relevant market data for the company.", "url": "https://www.moomoo.com/stock/VIVS-US/options-chain?chain_id=Name1K9-3FXPhg.1kvd400&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2FWTN-AU%2Fcompany%22%7D", "source_name": "Moomoo", "published_at": "2026-06-30T07:09:23", "published_display": "30 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "This article provides financial context for VivoSim Labs, Inc. (NASDAQ:VIVS) by focusing on its enterprise value to EBIT forward metric. It appears to be a stub or partial financial data point from TradingView, indicating no specific value or further details beyond the title. The", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:09:56", "published_display": "28 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "This article provides financial information for VivoSim Labs, Inc. (NASDAQ: VIVS), specifically focusing on its price-to-sales forward metric. It appears to be a financial snapshot from TradingView, offering a quick look at the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:09:23", "published_display": "28 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "The article provides a financial metric, \"Enterprise value to revenue forward,\" for VivoSim Labs, Inc. (NASDAQ: VIVS). It states that the market for VivoSim Labs, Inc. is currently closed with no trades. The content is presented within the context of TradingView's financial analy", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:41:07", "published_display": "27 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "This article focuses on the \"Price to earnings forward\" financial metric for VivoSim Labs, Inc. (NASDAQ: VIVS), as presented on TradingView. It appears to be a financial data page rather than a traditional article, providing a snapshot of a specific financial ratio for the compan", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:10:12", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Stock Soars After Major Distribution Deals in Asia", "summary": "VivoSim Labs Inc. (VIVS) stock surged by 82% after securing distribution agreements with JCBio in South Korea and Tekon Biotech in China for its NAMKind toxicology services. This strategic expansion into Asian markets aims to accelerate revenue growth, despite the company's curre", "url": "https://timothysykes.com/news/vivosimlabsinc-vivs-news-2026_01_31/", "source_name": "timothysykes.com", "published_at": "2026-06-14T11:41:33", "published_display": "14 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS - VivoSim Labs Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of VivoSim Labs Inc (VIVS) stock, including its latest stock price, financial data, and recent news. It details key financial metrics, insider ownership, analyst ratings, and a chronological list of company announcements and related ", "url": "https://finviz.com/stock?t=VIVS", "source_name": "Finviz", "published_at": "2026-05-30T06:40:18", "published_display": "30 May 2026 06:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS Q4'25 Earnings: EPS estimate is (2.04) USD", "summary": "VivoSim Labs, Inc. (VIVS) is scheduled to release its Q4'25 earnings on May 21st, with estimates placing revenue at 54.00 thousand USD and EPS at (2.04) USD. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC). This article provides a brief overview of the comp", "url": "https://www.tradingview.com/news/tradingview:300877429b350:0-vivs-q4-25-earnings-eps-estimate-is-2-04-usd/", "source_name": "TradingView", "published_at": "2026-05-20T11:09:08", "published_display": "20 May 2026 11:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VivoSim Labs Shares Surge 82% Amid Key Asia Distribution Deals", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE9oUXV2cXlYZk54TVI4WkFBaE5Gc2poVUlwVEdvbWtTTTFUazVQU0M5VHlGaXlVQ1lEdE5iY1ZrRWdfVVFjMEVZbWgwVVhYX0VId2I5aV9OY0k3NmVkOWhJSGljRGtNaE1GVEtJSWJuODlNZGtTUGc?oc=5", "source_name": "StocksToTrade", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is VivoSim Labs Stock a Hidden Gem?", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE4zZzNGM2FQUmJnbktjMEhNZURoVl9ZSUsyVmpWS2YzVWN3SzI3NlpoREVpdWx5MnRGRjVKYk80cnUxN1ktYnFDZktsYVloOC1MQjZ3aHJZWXR6VlgyeEFrVnVjRU5aMFVpeUsxUkFUY1d0TUxDZW0yUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs (VIVS) Stock Price, News & Analysis $VIVS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9SRW1aaUJSZjFOVnpIMW11bjkzY0pTUF9ickVlOEZUdG9DU3l2M2hzU3VhekdydDlHQWZIY0JsVWk5UV9lY0QzUl9KdmdfYlBwcmlZREhOd2JSZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-28T03:39:49+00:00", "published_display": "28 May 2025 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNREM4bGIyWkpPa0VMRGoxLXpFWHNxMXNJamdla1RzRHBNb0RCTVg5d3JMTUtvd2lkTy1oTUtLelQ3WDFacEV3Rlh4cTJOMkNfcmFVLVJTNVJFQzU3ZW5zNHMxdVNJN3M3SDNjUW8yazJvNVVCeXU4NDdLdHJBcUtNMW84VmZHSmRuT3FTWWpkRDNPVTh6UFVv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-23T07:00:00+00:00", "published_display": "23 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol \"VIVS\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPWVlWVkgwUGRUUlAtSk5ocF9RNzFsUEpxYVY5WkJTU2tIbGFKMi1hMFhRSzA5bndGN085Q3N1TnFLckszdUdpZGE4YXJQOXdJaW1iam5idXg3bUNpeldIZU1jaFFkcUFrRUZLTXRManJPVUlCUGZpU1pjZ2Q3VmZEU3ZoSWFmS0xMdXk0dVlkd1R5azlTNmtodlNDdGg2QW81VXNOWFlzWWVtQTJxQjNGblpwYVl4bW9VY0pGSWtEYVhYdXk0ZGU3UF9YQTNCbndLb2VN?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-04-23T07:00:00+00:00", "published_display": "23 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "VivoSim Enters China with First Commercial Sales of NAMkind\u2122 Toxicology Screening and Efficacy Testing Services", "summary": "VivoSim Labs, Inc. announced its first commercial sales in China for its NAMkind\u2122 toxicology screening and efficacy testing services, marking a significant expansion into the world's second-largest pharmaceutical market. The initial engagements involve a Shanghai-based oncology b", "url": "https://www.globenewswire.com/news-release/2026/07/21/3330426/0/en/VivoSim-Enters-China-with-First-Commercial-Sales-of-NAMkind-Toxicology-Screening-and-Efficacy-Testing-Services.html", "source_name": "GlobeNewswire", "published_at": "2026-07-22T03:10:29", "published_display": "22 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOMXp5YlRxRFJzMU53VnVTRmNMdi11MV9iZXNIaVZBdE4wNS1aUEZMdUZSTUxIb0lXNGN4bWhCQnV6Zks5SDFVMnNveEZwYzlnQ21tMXNwQm0yV2N5V245N01TZjlZbXk5V1BlM3pPYVYzUnQydW5oalg1T0Nrd056a2p1M1RIbFoyUHhOaUh5TmxzYXVVZVpXUEJKX1VNdERl?oc=5", "source_name": "Market source", "published_at": "2026-07-21T14:28:16+00:00", "published_display": "21 Jul 2026 14:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Enters China Market With Initial Preclinical Testing Contracts", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivosim-enters-china-market-initial-133504256.html", "source_name": "MT Newswires", "published_at": "2026-07-21T13:35:04+00:00", "published_display": "21 Jul 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Prices $4.0 Million Private Placement and Amends Legacy Armistice Warrants", "summary": "VivoSim Labs (VIVS) announced a $4.0 million private placement consisting of pre-funded and common warrants, with proceeds intended for working capital and general corporate purposes. The company engaged A.G.P./Alliance Global Partners as the placement agent. Additionally, VivoSi", "url": "https://www.tradingview.com/news/tradingview:441097d729cce:0-vivosim-labs-prices-4-0-million-private-placement-and-amends-legacy-armistice-warrants/", "source_name": "TradingView", "published_at": "2026-07-17T12:40:53", "published_display": "17 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxOSHllM2hCLXVQU3B3RWQ2cGFVU1dSV3k4WXNNc09NZGhTY0lITlAzdjlXUThlVGVscWpMZGZmOTZZVjJmanpiOXFSLXU5Nmp3Qm1HWGtROWkxVVJLUmxLYkpoRUZQWFRsVWE2SEpIX0hORFJBYlkyWlhWdjItTGpNN3d1eDQ0TlJPMThESnZneURMWHhmc1BCOUI3TzFsel9QS2VQTjFVdXl0R3lxcUVGR2dzbUlrUDRFU2xTZ2JRSHJvS1NxQnhPYzNVZkpLQS0zMmFhMTUyMG9MUnJHaEdzNzNjejE0Tm9Dc1RTcDdIMFVMQTctYUVPVmxvSmNWZndmMldNVmJrRG1NcGppRmIwVWxjTGFHZWdFT2F6REZ1NzNhcDg0UFdUVXQxT3dqdw?oc=5", "source_name": "Sahm", "published_at": "2026-07-17T07:51:56+00:00", "published_display": "17 Jul 2026 07:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is VivoSim Labs stock falling Thursday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWjlrTUNXTlpZYlNyQ1J2RXg2LV91SmtydmVnZ3lWUlIxbXNyLXZ5SXJFWjR5cGVNRExodWNSMHY3VFhESWpZdWIyb2pWNFdhM2o3OE1WeEo3ZkdCLWoxTUN3SlM3cnJGZ3ExMHBtMUk4aG5DaEZuY0swcDZxc0xLVVA0Z2RWQXFITm9mSzVZNVl2Wi1vakVweFEzcWYzdjBEN29uZEdDY3p3T3ZTQ0Ixc09R?oc=5", "source_name": "MSN", "published_at": "2026-07-17T07:00:00+00:00", "published_display": "17 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs prices USD 4 million private placement at USD 0.85 per share", "summary": "VivoSim Labs has priced a $4 million private placement at $0.85 per share and warrant with a single healthcare-focused institutional investor. The deal includes 4,705,883 common shares and warrants, with the warrants becoming exercisable after shareholder approval and expiring in", "url": "https://www.bitget.com/amp/news/detail/12560605510574", "source_name": "Bitget", "published_at": "2026-07-17T02:40:53", "published_display": "17 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment", "summary": "VivoSim Labs has secured $4.0 million through a private placement with a healthcare-focused institutional investor, involving the sale of common stock and warrants at $0.85 per share. Existing warrants will also be amended to lower their exercise price to $0.85, subject to shareh", "url": "https://www.quiverquant.com/news/VivoSim+Labs+Announces+$4.0+Million+Private+Placement+with+Institutional+Investor+and+Warrant+Amendment", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T01:40:17", "published_display": "17 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs raises $4M in private placement", "summary": "VivoSim Labs (NASDAQ:VIVS) has raised approximately $4.0 million through a private placement with a healthcare-focused institutional investor, selling shares and warrants at $0.85 per share. The company will use these proceeds for working capital and general corporate purposes. T", "url": "https://m.uk.investing.com/news/stock-market-news/vivosim-labs-raises-4m-in-private-placement-93CH-4774090?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-17T00:40:12", "published_display": "17 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs raises $4M in private placement By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNRTZWeDUzbnRYUDhrRW1FQmw0MTFJWlluTzN2c2QwVVRZMEdEVHlZQmFFS09fNjhBaUVxVk9Rc0tqVVZuSUtmRXlpdlFlMmRDYmdvb1NUdDE4RHFCdG9ibFFIT0IzSzRoTElVVHNfdjFTeGUyaDhnS1QyVWlUcXMtaXZObXpra0l0S1U2VTk3Z2RFYW9OQlhtMHBjRUxfZGpNOWIwMGRpcw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T22:32:09+00:00", "published_display": "16 Jul 2026 22:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Prices $4 Million Private Placement of Stock, Warrants; Shares Fall Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vivosim-labs-prices-4-million-131934088.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:19:34+00:00", "published_display": "16 Jul 2026 13:19", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs, Inc. announced that it expects to receive $4.000001 million in funding", "summary": "VivoSim Labs, Inc. has announced a securities purchase agreement with a healthcare-focused institutional investor for $4,000,000.55 in gross proceeds. This funding involves the sale of 4,705,883 common shares and pre-funded warrants, with an issue price and exercise price of $0.8", "url": "https://www.marketscreener.com/news/vivosim-labs-inc-announced-that-it-expects-to-receive-4-000001-million-in-funding-ce7f5ed3d18af225", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T13:09:39", "published_display": "16 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vivosim Labs Shares Are Rocketing on Wednesday?", "summary": "VivoSim Labs Inc. (NASDAQ: VIVS) shares surged on Wednesday due to a $5 million milestone payment received from Eli Lilly and Company (NYSE: LLY) and optimistic revenue guidance for FY2027, anticipating over 500% growth. The payment was triggered by the first patient being dosed ", "url": "https://www.sahmcapital.com/news/content/why-vivosim-labs-shares-are-rocketing-on-wednesday-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T10:12:21", "published_display": "16 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Sees FY27 Rev Growing Significantly >VIVS", "summary": "VivoSim Labs (VIVS) projects significant revenue growth for fiscal year 2027. The company's outlook indicates a strong financial performance in the coming years. This forecast suggests positive momentum for VIVS.", "url": "https://www.moomoo.com/news/post/73010316/vivosim-labs-sees-fy27-rev-growing-significantly-vivs", "source_name": "Moomoo", "published_at": "2026-07-16T02:10:05", "published_display": "16 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is VivoSim Labs stock sliding today?", "summary": "VivoSim Labs (VIVS) stock slid 1.5% in after-hours trading, reversing an intraday surge. The initial rally was triggered by a $5 million milestone payment from Eli Lilly and a projection of over 500% revenue growth for fiscal year 2027 due to demand for its NAMkind 3D cellular mo", "url": "https://www.investing.com/news/stock-market-news/why-is-vivosim-labs-stock-sliding-today-93CH-4794427", "source_name": "Investing.com", "published_at": "2026-07-16T00:15:35", "published_display": "16 Jul 2026 00:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs (NASDAQ:VIVS) hits $5M milestone; company says 500% revenue jump comes off $131K base", "summary": "VivoSim Labs (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly and Company (NYSE:LLY) after the first patient was dosed in a Phase 2 trial for an inflammatory bowel drug. Despite this significant payment, which is 1.7 times VivoSim\u2019s equity value, shares closed", "url": "https://ts2.tech/en/vivosim-labs-nasdaqvivs-hits-5m-milestone-company-says-500-revenue-jump-comes-off-131k-base/", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T21:15:35", "published_display": "15 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim receives $5M milestone payment from Eli Lilly By Investing.com", "summary": "VivoSim Labs Inc. (NASDAQ:VIVS) announced today it has received a $5 million milestone payment from Eli Lilly related to a former inflammatory bowel disease drug program. This payment marks the dosing of the first patient in Phase 2 studies of the drug, with potential for up to $", "url": "https://ng.investing.com/news/stock-market-news/vivosim-receives-5m-milestone-payment-from-eli-lilly-93CH-2600771", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T20:12:06", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs (VIVS) Forecasts 500% Revenue Growth, Secures $5M M", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNa2JWelFUVHFGX0ZOTmJza3VNbTFXRmcyVHlqR1RuaEV4TWZvWGFoc3dwRWs1MjRTUTk5cjlLaVAyemhlekctNjdueFNmWFIxcFpUMG5GU0FoazFqdjNpUS1aYUs0ZWhtby1naVh0X1NlVkMwcWR2RzJnaFNvVnJsS2QzekNrVmFuOGw4V0YtYWRjM0J5YUE1XzlqSGlROHJYVDVGQ3pfd1k1MndKSnhyU0QzeXY1YVVWQm91RVM1Ym5qcHpX?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T19:00:47+00:00", "published_display": "15 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Rallies on Heavy Volume After Late Annual Report Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPYmNoTXZmZDd5WjIyVW1EQTBPQ0Fka3VSbkdPcXJLSENhQ1p5MFJxb2tmY3Vrd18wcUkyeXpkVGpTY2VaUUJGN2ZfS0RBNzFMZmxzbHlIb2pvb2VKSDNoQnMwUW4xWmdEZXd1N1o1NU1obGZQdW5nSXhNbjRhQUZ5Z2xrS2d1M0kwZkZMS1lDZHNxazVzcTBjcVFyY2I4TzhpYkpR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T16:21:00+00:00", "published_display": "15 Jul 2026 16:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim receives $5 million Eli Lilly milestone", "summary": "VivoSim received a $5 million milestone payment from Eli Lilly after the first patient was dosed in Phase 2 studies for an acquired inflammatory bowel disease (IBD) drug. VivoSim, which sold its FXR314 IBD program to Eli Lilly in March 2025, could earn an additional $45 million i", "url": "https://grafa.com/en/news/united-states/vivosim-5-million-eli-lilly-milestone-fy2027-guidance", "source_name": "grafa.com", "published_at": "2026-07-15T17:15:35", "published_display": "15 Jul 2026 17:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth", "summary": "", "url": "https://finance.yahoo.com/m/8711fa04-b005-37fb-ab5a-a936fdf8de8b/vivosim-receives-%245-million.html", "source_name": "InvestorsHub", "published_at": "2026-07-15T14:46:50+00:00", "published_display": "15 Jul 2026 14:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs stock falls 29% on $4M private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdWdoLWlxOUVacXlpc0VFa1gyTlpGNGhUbkNZZjhGdkVSMlVWR3BXX1RkR1lsY3k1ckw4YzkybDI1eGZneWlBaTJ6aHRsaXFIMXZnVDFwQzdaUklkY1E5UDExWF96Q0hWUkZlZHZHWWNrbmk5cUF2WjN3aDN5d3NtY1ZDaFRGeUJhUFlESzQ4NnNkUldTVFp3eXphbTZ5c1FuREtBTFkydw?oc=5", "source_name": "scanx.trade", "published_at": "2026-07-15T14:10:33+00:00", "published_display": "15 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Receives $5 Million Eli Lilly Milestone Payment, Issues Fiscal 2027 Revenue Growth Outlook", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivosim-receives-5-million-eli-131234676.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:12:34+00:00", "published_display": "15 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS Stock Whipsaws As Traders Target Volatile Moves", "summary": "VivoSim Labs Inc. (VIVS) stock is experiencing extreme volatility, with prices swinging dramatically from premarket spikes to sharp intraday drops. The company, an early-stage story with minimal revenue ($40,000 quarterly) and significant losses (net loss of $5.76M), is attractin", "url": "https://stockstotrade.com/news/vivosim-labs-inc-vivs-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T14:08:00", "published_display": "15 Jul 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027", "summary": "VivoSim Labs, Inc. announced receipt of a $5 million milestone payment from Eli Lilly related to an inflammatory bowel disease drug program previously sold to Lilly, triggered by the dosing of the first patient in Phase 2 studies. VivoSim remains eligible for up to an additional ", "url": "https://sg.finance.yahoo.com/news/vivosim-receives-5m-milestone-payment-120500732.html", "source_name": "Market source", "published_at": "2026-07-15T12:15:35", "published_display": "15 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS Stock Whipsaws As Traders Zero In On Cash Runway", "summary": "VivoSim Labs Inc. (VIVS) stock experienced significant volatility, driven by news of an AI partnership. Despite low revenue ($40,000) and substantial net losses ($5.76M), the company maintains a cash buffer of $5.0M and low debt, attracting speculative traders due to its early-st", "url": "https://www.timothysykes.com/news/vivosim-labs-inc-vivs-news-2026_07_15/", "source_name": "www.timothysykes.com", "published_at": "2026-07-15T09:18:00", "published_display": "15 Jul 2026 09:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Phase 2 Patient Brings VivoSim a $5M Lilly Payment", "summary": "VivoSim (VIVS) announced it received a $5 million milestone payment from Eli Lilly, contingent on the first patient dosing in Phase 2 studies for an inflammatory bowel disease drug VivoSim previously sold. The company is eligible for an additional $45 million in milestones and pr", "url": "https://www.stocktitan.net/news/VIVS/vivo-sim-receives-5m-milestone-payment-from-eli-lilly-provides-omwzf1tsza0a.html", "source_name": "Stock Titan", "published_at": "2026-07-15T08:05:00", "published_display": "15 Jul 2026 08:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim: Fiscal Q4 Earnings Snapshot", "summary": "VivoSim Labs, Inc. (VIVS) reported a fiscal fourth-quarter net loss of $5.8 million, or $2.21 per share, with revenues of $40,000. For the full year, the company's loss totaled $13.8 million, or $5.35 per share, on revenues of $131,000. VivoSim Labs is a development-stage company", "url": "https://www.ktvb.com/article/syndication/associatedpress/vivosim-fiscal-q4-earnings-snapshot/616-6e456e35-fc14-4480-bb1a-28886fd71185", "source_name": "KTVB", "published_at": "2026-07-14T21:10:27", "published_display": "14 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting", "summary": "VivoSim Labs, Inc. announced that data from its advanced 3D human tissue models will be featured at the European Society of Toxicology\u2019s annual conference. The data demonstrate the superior predictive power of VivoSim's AI-enabled NAMkind\u2122 Liver and NAMkind\u2122 GI platforms for live", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318919/37000/en/vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-prediction-at-european-toxicology-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T07:09:23", "published_display": "30 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs(VIVS) Stock Options Chain | Quotes & News", "summary": "This article provides financial information for VivoSim Labs (VIVS), including its stock options chain, quotes, and related news. It serves as a portal for investors to access relevant market data for the company.", "url": "https://www.moomoo.com/stock/VIVS-US/options-chain?chain_id=Name1K9-3FXPhg.1kvd400&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2FWTN-AU%2Fcompany%22%7D", "source_name": "Moomoo", "published_at": "2026-06-30T07:09:23", "published_display": "30 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "This article provides financial context for VivoSim Labs, Inc. (NASDAQ:VIVS) by focusing on its enterprise value to EBIT forward metric. It appears to be a stub or partial financial data point from TradingView, indicating no specific value or further details beyond the title. The", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:09:56", "published_display": "28 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "This article provides financial information for VivoSim Labs, Inc. (NASDAQ: VIVS), specifically focusing on its price-to-sales forward metric. It appears to be a financial snapshot from TradingView, offering a quick look at the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:09:23", "published_display": "28 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "The article provides a financial metric, \"Enterprise value to revenue forward,\" for VivoSim Labs, Inc. (NASDAQ: VIVS). It states that the market for VivoSim Labs, Inc. is currently closed with no trades. The content is presented within the context of TradingView's financial analy", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:41:07", "published_display": "27 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of VivoSim Labs, Inc. \u2013 NASDAQ:VIVS", "summary": "This article focuses on the \"Price to earnings forward\" financial metric for VivoSim Labs, Inc. (NASDAQ: VIVS), as presented on TradingView. It appears to be a financial data page rather than a traditional article, providing a snapshot of a specific financial ratio for the compan", "url": "https://www.tradingview.com/symbols/NASDAQ-VIVS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:10:12", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Stock Soars After Major Distribution Deals in Asia", "summary": "VivoSim Labs Inc. (VIVS) stock surged by 82% after securing distribution agreements with JCBio in South Korea and Tekon Biotech in China for its NAMKind toxicology services. This strategic expansion into Asian markets aims to accelerate revenue growth, despite the company's curre", "url": "https://timothysykes.com/news/vivosimlabsinc-vivs-news-2026_01_31/", "source_name": "timothysykes.com", "published_at": "2026-06-14T11:41:33", "published_display": "14 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS - VivoSim Labs Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of VivoSim Labs Inc (VIVS) stock, including its latest stock price, financial data, and recent news. It details key financial metrics, insider ownership, analyst ratings, and a chronological list of company announcements and related ", "url": "https://finviz.com/stock?t=VIVS", "source_name": "Finviz", "published_at": "2026-05-30T06:40:18", "published_display": "30 May 2026 06:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIVS Q4'25 Earnings: EPS estimate is (2.04) USD", "summary": "VivoSim Labs, Inc. (VIVS) is scheduled to release its Q4'25 earnings on May 21st, with estimates placing revenue at 54.00 thousand USD and EPS at (2.04) USD. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC). This article provides a brief overview of the comp", "url": "https://www.tradingview.com/news/tradingview:300877429b350:0-vivs-q4-25-earnings-eps-estimate-is-2-04-usd/", "source_name": "TradingView", "published_at": "2026-05-20T11:09:08", "published_display": "20 May 2026 11:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs Shares Surge 82% Amid Key Asia Distribution Deals", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE9oUXV2cXlYZk54TVI4WkFBaE5Gc2poVUlwVEdvbWtTTTFUazVQU0M5VHlGaXlVQ1lEdE5iY1ZrRWdfVVFjMEVZbWgwVVhYX0VId2I5aV9OY0k3NmVkOWhJSGljRGtNaE1GVEtJSWJuODlNZGtTUGc?oc=5", "source_name": "StocksToTrade", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is VivoSim Labs Stock a Hidden Gem?", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE4zZzNGM2FQUmJnbktjMEhNZURoVl9ZSUsyVmpWS2YzVWN3SzI3NlpoREVpdWx5MnRGRjVKYk80cnUxN1ktYnFDZktsYVloOC1MQjZ3aHJZWXR6VlgyeEFrVnVjRU5aMFVpeUsxUkFUY1d0TUxDZW0yUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VivoSim Labs (VIVS) Stock Price, News & Analysis $VIVS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9SRW1aaUJSZjFOVnpIMW11bjkzY0pTUF9ickVlOEZUdG9DU3l2M2hzU3VhekdydDlHQWZIY0JsVWk5UV9lY0QzUl9KdmdfYlBwcmlZREhOd2JSZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-28T03:39:49+00:00", "published_display": "28 May 2025 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNREM4bGIyWkpPa0VMRGoxLXpFWHNxMXNJamdla1RzRHBNb0RCTVg5d3JMTUtvd2lkTy1oTUtLelQ3WDFacEV3Rlh4cTJOMkNfcmFVLVJTNVJFQzU3ZW5zNHMxdVNJN3M3SDNjUW8yazJvNVVCeXU4NDdLdHJBcUtNMW84VmZHSmRuT3FTWWpkRDNPVTh6UFVv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-23T07:00:00+00:00", "published_display": "23 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol \"VIVS\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPWVlWVkgwUGRUUlAtSk5ocF9RNzFsUEpxYVY5WkJTU2tIbGFKMi1hMFhRSzA5bndGN085Q3N1TnFLckszdUdpZGE4YXJQOXdJaW1iam5idXg3bUNpeldIZU1jaFFkcUFrRUZLTXRManJPVUlCUGZpU1pjZ2Q3VmZEU3ZoSWFmS0xMdXk0dVlkd1R5azlTNmtodlNDdGg2QW81VXNOWFlzWWVtQTJxQjNGblpwYVl4bW9VY0pGSWtEYVhYdXk0ZGU3UF9YQTNCbndLb2VN?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-04-23T07:00:00+00:00", "published_display": "23 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 51, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 32, "score": 53, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 0.58, "latest_week": "2026-07-17", "one_week_move": -34.1, "four_week_move": -47.4, "twelve_week_move": -60.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.324972, "market_dynamics_buy_signal": false, "relative_strength": -74.381932, "fair_value_gap": -91.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 37.5779, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-34.1% over one week, -47.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "MT Newswires", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "StocksToTrade", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "Sahm", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 21}, {"label": "Guidance", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-34.1% over one week, -47.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "VivoSim Enters China with First Commercial Sales of NAMkind\u2122 Toxicology Screening and Efficacy Testing Services"}], "updated_at": "2026-07-23T07:08:30.465548+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}